Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

An Observational Study for the Assessment of Compliance and Persistence to Rebif® Therapy of Patients With Relapsing-remitting Multiple Sclerosis (MS) and Evaluation of Potential Factors Influencing These Parameters

This study has been completed.
Merck A.E., Greece
Information provided by (Responsible Party):
Merck KGaA Identifier:
First received: April 26, 2010
Last updated: July 15, 2014
Last verified: July 2014
The present study aims to assess the adherence to therapy with interferon beta-1a (Rebif®) and at investigating potential factors that are involved in its outcome, in a representative sample of patients with relapsing remitting multiple sclerosis (RRMS), under real life conditions.

Multiple Sclerosis, Relapsing-Remitting

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: A Multicentre, Non Interventional, Non Randomized, Observational Study for the Assessment of Compliance and Persistence With Rebif® Therapy of Patients With Relapsing-Remitting Multiple Sclerosis as Well as for the Evaluation of Potential Factors Influencing These Parameters, in Real Life Clinical Practice

Resource links provided by NLM:

Further study details as provided by Merck KGaA:

Primary Outcome Measures:
  • Assessment of subjects' compliance with physicians' instructions on the proper use of the treatment [ Time Frame: Preceding 2 weeks prior to subjects enrolment into the study ]
    Evaluation of the actual number of injections administered during the preceding 2 weeks prior to subjects' enrolment into the study

  • Assessment of subjects' compliance with physicians' instructions on the proper use of the treatment after 6 months of therapy [ Time Frame: From preceding 2 weeks prior to the first visit (Month 1) till the final visit (Month 6) of the study ]
    Evaluation of the number of injections actually administered over the preceding 2 weeks prior to the first and the final visit of the study

  • Assessment of subjects' persistence to therapy [ Time Frame: Since subjects' enrolment until final study visit (Month 6) ]
    Assessment will include recording of the number of days under treatment since subjects' enrolment into the study and until the performance of the study final visit, at Month 6.

Secondary Outcome Measures:
  • Assessment of the factors and their potential correlation with the defined subjects' compliance and persistence to therapy [ Time Frame: Subjects' enrollment to final study visit (Month 6) ]
    Subject's training regarding proper administration of the study drug and proper use of auto-injector of the study drug (Rebiject II); implementation by subject of the recommendations for treatment administration and instructions on the proper use of device (via prefilled syringe or auto-injector); prophylactic use of non steroidal anti-inflammatory drugs (NSAIDs); reasons for missed injections; EDSS score at baseline; relapse history prior to Rebif therapy initiation; MS treatments received by the subject during the preceding year before Rebif therapy commencement

Enrollment: 133
Study Start Date: December 2009
Study Completion Date: September 2012
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Detailed Description:

In the relapsing-remitting type of the disease the objective of the therapy is the reduction of relapse rate, duration and severity, as well as the delay of transition to the progressive form of the disease. Subjects' adherence to long-term therapy of MS plays a pivotal role in the optimization of therapeutic outcome and maximization of the derived clinical benefit for the treated subjects. Rebif current formulation has been developed by assessing and refining the physicochemical characteristics of existing formulations aiming at further improving product's tolerability profile. Studies performed for the assessment of Rebif have demonstrated a 3-fold reduction in injection site reactions as well as improved overall tolerability and safety profile.

This is a multicentre, prospective, non interventional, non randomized, open label study for the assessment of the adherence to therapy with Rebif of subjects with RRMS. The participating subjects shall be already on treatment with (Rebif) prior to their enrolment into the study, according to the approved Summary of Product Characteristics (SPC) and the clinical, imaging and laboratory findings of the disease, as evaluated by their treating physician, in real life clinical practice. Data will be collected retrospectively from a sample of 150 subjects' medical files and through questions that will be posed to the subjects, and prospectively during the course of the study. The total duration of the study is estimated to be 18 months.


Primary objective:

  • To assess the compliance and persistence with Rebif therapy in MS subjects, after six months of therapy, in "real life" clinical settings in Greece

Secondary objective:

  • To investigate the potential factors influencing compliance and persistence to Rebif therapy.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Subjects with documented diagnosis of RRMS according to the McDonald criteria (2005)

Inclusion Criteria:

  • Subjects with documented diagnosis of RRMS according to the Mc Donald criteria (2005)
  • Subjects who have already been administered therapy with IFN b-1a (Rebif) according to the approved product's Summary of Product Characteristics (SPC), at least two weeks and not longer than six weeks prior to their enrolment into the study
  • Subjects of both genders, aged between 18 - 65 years (inclusive)
  • Expanded Disability Status Scale (EDSS) score < 6 (inclusive) at baseline (before Rebif therapy initiation)
  • Subjects who are able to read and understand the Patient Information Leaflet
  • Subjects who have signed the Informed Consent Form
  • Subjects who are willing and capable to comply will all study requirements and procedures.

Exclusion Criteria:

  • Subjects that meet any of the contraindications to the administration of the study drug according to the approved SPC
  • Subjects with primary progressive or secondary progressive form of MS
  • Subjects who have been treated with Rebif for less than two weeks and more than six weeks before their enrollment into the study
  • Subjects who had been receiving any therapy for MS (other disease modifying drugs, immunomodulatory and/or immunosuppressive agents) within three months before Rebif therapy commencement
  • History of any chronic pain syndrome
  • Current or past (during the preceding two years) history of alcohol or drug abuse
  • Women who are pregnant or breastfeeding or of childbearing potential that do not use any medically accepted method of contraception
  • Subjects who are currently participating or had participated in another clinical trial during the last three months prior to their enrolment
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01112345

Henry Dunant Hospital - IRB
Athens, Greece, 11526
Sponsors and Collaborators
Merck KGaA
Merck A.E., Greece
Study Director: Michalis Arvanitis, MD Merck A.E., Greece
  More Information

Responsible Party: Merck KGaA Identifier: NCT01112345     History of Changes
Other Study ID Numbers: EMR 701068-513
Study First Received: April 26, 2010
Last Updated: July 15, 2014

Keywords provided by Merck KGaA:
Multiple Sclerosis, Relapsing-Remitting

Additional relevant MeSH terms:
Multiple Sclerosis
Multiple Sclerosis, Relapsing-Remitting
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases processed this record on May 25, 2017